A recent, retrospective nationwide study from Austria showed that, at a median follow-up of 20 months, MG patients (70% AChRab positive, 25% MuSK positive) treated with rituximab achieved remission in about 43% and minimal manifestations in 25% (70). The gene discussed is MUSK; the disease is myasthenia gravis.